International Flavors & Fragrances Inc.

What is International Flavors & Fragrances?
IFF is a New York-based ingredients company that creates flavors, fragrances, and bioscience products used in food, beverage, home, and personal care goods worldwide. FY2025 sales were $10.89 billion.

Is IFF publicly traded?
Yes. It trades on the New York Stock Exchange under the ticker IFF.

Who is the CEO of IFF?
Erik Fyrwald, formerly CEO of Syngenta, has led IFF since February 2022.

What are IFF's business segments?
Taste, Food Ingredients, Health & Biosciences, and Scent. The former Pharma Solutions unit was sold to Roquette in May 2025.

What was the DuPont merger?
In February 2021 IFF combined with DuPont's Nutrition & Biosciences business in a reverse morris trust transaction valuing the company at roughly $45 billion, adding probiotics, enzymes, and plant proteins.

Polak & Schwarz was founded in Zutphen, Netherlands in 1889, and van Ameringen-Haebler traces to 1929 in New York. Their 1958 merger created International Flavors & Fragrances, a transatlantic ingredients house that grew with the postwar consumer goods boom.

Decades of acquisitions followed, including Israeli flavors maker Frutarom in 2018 for about $7.1 billion. The largest move came in February 2021: a reverse morris trust merger with DuPont's Nutrition & Biosciences business, valuing the combined enterprise at roughly $45 billion and bringing probiotics, enzymes, cultures, and plant proteins into the portfolio.

The expanded portfolio proved heavy. From 2023 IFF ran a divestiture program to cut debt, selling its Lucas Meyer Cosmetics business to Clariant and divesting the Pharma Solutions and Nitrocellulose businesses to Roquette in May 2025. From January 2025 it resegmented the former Nourish division into Taste and Food Ingredients reporting lines. FY2025 sales were $10.89 billion, down 5% on a reported basis but up 2% on a comparable currency-neutral basis.

IFF publishes sustainability reporting covering responsible sourcing of naturals, bioscience-based product development positioned as lower-impact alternatives, and operational emissions. Its Health & Biosciences portfolio includes enzyme and probiotic products marketed on sustainability benefits.

In 2023 an internal investigation found improper accounting at two units, forcing IFF to restate results and drawing regulatory scrutiny and management changes; the company settled the matter with remediated controls. The heavy debt load taken on for the DuPont merger also attracted sustained investor criticism addressed through the subsequent divestiture program.